3 unknown. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 3 |
| Phase 3 | 1 | Unknown 1 |
Follow Pathological Complete Response: new trials by email Literature Review of Pathological Complete Response trials Research Report on Pathological Complete Response
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy Camrelizumab with vinorelbine and cisplatin - HER2-negative Breast Cancer, Neoadjuvant Therapy | Phase 2 | Unknown | Peking University First Hospital | 30 | 2021-11-20 | 2022-10-18 |
| Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME, concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX - Rectal Cancer, Pathological Complete Response | Phase 2 | Unknown | Peking University People's Hospital | 244 | 2018-01-31 | 2023-03-22 |
| Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy Epirubicin, Fluorouracil, Docetaxel - Breast Cancer, Pathological Complete Response | Phase 2 / Phase 3 | Unknown | Zhiyong Yu | 200 | 2017-11-27 | 2017-11-21 |
Breast Neoplasms (1) · Rectal Neoplasms (1)
Neoplasms (2) · Neoplasms by Site (2) · Breast Diseases (1) · Colorectal Neoplasms (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Rectal Diseases (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
Cisplatin (1) · Cyclophosphamide (1) · Docetaxel (1) · Doxorubicin (1) · Epirubicin (1) · Fluorouracil (1) · Vinorelbine (1) · camrelizumab (1)
Peking University First Hospital (1) · Peking University People's Hospital (1) · Zhiyong Yu (1)
China (2)
Xiaoshan Cao, MD (1) · Zhiyong Yu, PhD (1)
PMID 20106720, PMID 21066983, PMID 21596621, PMID 21747092, PMID 22367706, PMID 22529255, PMID 26187751, PMID 26189067, PMID 27254838, PMID 27480145